In line with these observations, CD70 CAR-T cells engineered to secrete anti-CD33/anti-CD3 dual-targeting antibodies display potent anti-AML activity and are able to bypass CD70 antigen escape [65]. The gene discussed is CD33; the disease is acute myeloid leukemia.